活血祛风颗粒配合窄谱中波紫外线治疗白癜风疗效观察

目的：观察活血祛风颗粒配合窄谱中波紫外线照射治疗白癜风的疗效和安全性。方法：收集2012年8月～2013年4月期间在我院就诊的362例白癜风患者随机分为研究组与对照组，研究组187例内服活血祛风颗粒配合窄谱中波紫外线照射治疗，对照组175例单纯进行窄谱中波紫外线照射治疗，3个疗程判定结果。结果：研究组痊愈率为84.0%，总有效率为92.5%，对照组痊愈率为41.7%，总有效率为72.6%。研究组痊愈率与总有效率均高于对照组，两组痊愈率、总有效率比较差异有显著性（P<0.05）。结论：活血祛风颗粒配合窄谱中波紫外线治疗白癜风疗效显著。     

Learning from nature – Novel synthetic biology approaches for biomaterial design

Many biomaterials constructed today are complex chemical structures that incorporate biologically active components derived from nature, but the field can still be said to be in its infancy. The need for materials that bring sophisticated properties of structure, dynamics and function to medical and non-medical applications will only grow. Increasing appreciation of the functionality of biological systems has caused biomaterials researchers to consider nature for design inspiration, and many examples exist of the use of biomolecular motifs. Yet evolution, nature’s only engine for the creation of new designs, has been largely ignored by the biomaterials community. Molecular evolution is an emerging tool that enables one to apply nature’s engineering principles to non-natural situations using variation and selection. The purpose of this review is to highlight the most recent advances in the use of molecular evolution in synthetic biology applications for biomaterial engineering, and to discuss some of the areas in which this approach may be successfully applied in the future.     

Comparison of P25 and nanobelts on Kruppel-like factor-mediated nitric oxide pathways in human umbilical vein endothelial cells

Recently, we reported that titanium dioxide (TiO₂) materials activated endothelial cells via Kruppel-like factor (KLF)-mediated nitric oxide (NO) dysfunction, but the roles of physical properties of materials are not clear. In this study, we prepared nanobelts from P25 particles and compared their adverse effects to human umbilical vein endothelial cells (HUVECs). TiO₂ nanobelts had belt-like morphology but comparable surface areas as P25 particles. When applied to HUVECs, P25 particles or nanobelts did not induce cytotoxicity, although nanobelts were much more effective to increase intracellular Ti element concentrations compared the same amounts of P25 particles. Only nanobelts significantly induced THP-1 adhesion onto HUVECs. Consistently, nanobelts were more significant to induce the expression of intracellular adhesion molecule-1 (ICAM1) and the release of soluble ICAM-1 (sICAM-1), indicating that nanobelts were more potent to induce endothelial activation in vitro. As the mechanisms for endothelial activation, both P25 and nanobelts reduced the generation of intracellular NO as well as the expression of NO regulators KLF2 and KLF4. Combined, the results from this study indicated that the different morphologies of P25 particles and nanobelts only changed their internalization into HUVECs but showed minimal impact on KLF-mediated NO signaling pathways.     

评价一次性使用输血器具用尼龙血液过滤网过滤性能的新方法

建立一种使用240μm和160μm的标准粒子溶液评价尼龙血液过滤网过滤性能新方法,代替传统人体血液的评价方法。并通过试验证实,用该方法评价过滤网的过滤性能具有良好的重复性,操作简便、试验材料可得性强、避免因使用血液带来的安全隐患等优点。可用于尼龙血液过滤网和输血器生产的过程控制。     

百蕊颗粒辅助治疗小儿急性上呼吸道感染临床观察

摘 要 目的： 观察百蕊颗粒辅助治疗小儿急性上呼吸道感染的临床疗效。方法: 180例急性上呼吸道感染患儿随机分为对照组和观察组各90例。在常规治疗基础上,对照组予利巴韦林10 mg·kg^-1·d^-1,qd,观察组在对照组基础上再加用百蕊颗粒。比较两组临床疗效,主要临床症状体征改善时间、住院时间及药品不良反应。结果:除啰音消失时间外,观察组临床症状体征改善时间及住院时间均较对照组明显缩短（P<0.05）;观察组显效率、总有效率均明显高于对照组（P<0.05）。两组药品不良反应发生率比较,差异无统计学意义（P>0.05）。结论: 百蕊颗粒辅助治疗小儿急性上呼吸道感染能显著改善患儿症状体征,疗效显著,值得临床推广。     

地衣芽孢杆菌活菌颗粒杂菌检查方法验证

目的 建立地衣芽孢杆菌活菌颗粒杂菌检查方法。方法 控制菌检查采用平皿涂布法;非致病性杂菌检查以杂菌率不得过0.1%为限度指标,采用营养琼脂平皿涂布法37 ℃培养;真菌计数采用玫瑰红钠琼脂平皿涂布法25 ℃培养。结果 控制菌检查、非致病性杂菌检查和真菌计数方法均满足中国药典2010年版验证试验的基本要求。结论 该方法可作为地衣芽孢杆菌活菌颗粒杂菌检查方法。     

An evaluation of RVX-208 for the treatment of atherosclerosis

Introduction: RVX-208 is a first-in-class, orally active, novel small molecule in development by Resverlogix Corporation (Calgary, AB, Canada). It acts through an epigenetic mechanism by inhibiting the bromodomain and extraterminal (BET) family of proteins, increasing apolipoprotein A-I (apoA-I) and targeting high-density lipoprotein (HDL) metabolism, including generating of nascent HDL and increased larger HDL particles, resulting in the stimulation of reverse cholesterol transport. RVX-208 also has a beneficial effect on inflammatory factors known to be involved in atherosclerosis and plaque stability. New therapeutic strategies are needed for patients with atherosclerosis.

Areas covered: In this review, the authors evaluate the use of RVX-208 as an agent for the treatment of atherosclerosis. The article is based on a literature search considering both animal and human studies available on PubMed as well as Media Releases from the Resverlogix Corporation.

Expert opinion: The current evidence suggests promising beneficial effects of this novel drug in the prevention and treatment of atherosclerosis and other metabolic disorders. Its unique mechanism of action is encouraging; it affects several pathways and has a modest effect on HDL levels. There is also a shift in particle size to larger HDL particles, which may have potent atheroprotective effects. Future clinical development is needed, including safety assessment.     

通乐颗粒治疗慢性功能性便秘阴虚肠燥证临床研究

目的:观察通乐颗粒治疗慢性功能性便秘(chronic functional constipation,CFC)阴虚肠燥证的疗效及对血清超氧化物歧化酶(superoxide dismutase,SOD)和胃动素(motilin,MTL)的影响。方法:114例功能性便秘阴虚肠燥证患者按数字表随机分为治疗组57例和对照组57例。对照组参照《中国慢性便秘诊治指南》制定标准给予治疗;治疗组内服通乐颗粒每次12 g,2次·d-1;所有患者均给予4周治疗。比较两组中医临床症状评分和主要临床症状评分;检测两组血清SOD和MTL水平。结果:治疗组治疗后中医临床症状积分均显著低于对照组(P0.01);治疗组临床有效率为98.25%,对照组有效率为82.46%,两组比较,差异有统计学意义(P0.05);治疗组治疗后主要症状评分均低于同期对照组(P0.01);治疗组治疗后SOD和MTL水平均明显高于对照组,两组比较,差异有统计学意义(P0.01)。结论:通乐颗粒治疗CFC阴虚肠燥证可明显改善临床症状,提高临床疗效,升高血清SOD和MTL。     

Immunogenicity and performance of an enterovirus 71 virus-like-particle vaccine in nonhuman primates

A vaccine against human enterovirus 71 (EV-A71) is urgently needed to combat outbreaks of EV-A71 and in particular, the serious neurological complications that manifest during these outbreaks. In this study, an EV-A71 virus-like-particle (VLP) based on a B5 subgenogroup (EV-A71-B5 VLP) was generated using an insect cell/baculovirus platform. Biochemical analysis demonstrated that the purified VLP had a highly native procapsid structure and initial studies in vivo demonstrated that the VLPs were immunogenic in mice. The impact of VLP immunization on infection was examined in non-human primates using a VLP prime-boost strategy prior to EV-A71 challenge. Rhesus macaques were immunized on day 0 and day 21 with VLPs (100 μg/dose) containing adjuvant or with adjuvant alone (controls), and were challenged with EV-A71 on day 42. Complete blood counts, serum chemistry, magnetic resonance imaging (MRI) scans, and histopathology results were mostly normal in vaccinated and control animals after virus challenge demonstrating that the fatal EV-A71-B3 clinical isolate used in this study was not highly virulent in rhesus macaques. Viral genome and/or infectious virus were detected in blood, spleen or brain of two of three control animals, but not in any specimens from the vaccinated animals, indicating that VLP immunization prevented systemic spread of EV-A71 in rhesus macaques. High levels of IgM and IgG were detected in VLP-vaccinated animals and these responses were highly specific for EV-A71 particles and capsid proteins. Serum from vaccinated animals also exhibited similar neutralizing activity against different subgenogroups of EV-A71 demonstrating that the VLPs induced cross-neutralizing antibodies. In conclusion, our EV-A71-B5 VLP is safe, highly immunogenic, and prevents systemic EV-A71-B3 infection in nonhuman primates making it a viable attractive vaccine candidate for EV-A71.     

Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial

BackgroundThis study aimed to investigate the dosage, immunogenicity and safety profile of a novel human papillomavirus (HPV) types 16 and 18 bivalent vaccine produced by E. coli.MethodsThis randomized, double-blinded, controlled phase 2 trial enrolled women aged 18–25 years in China. Totally 1600 eligible participants were randomized to receive 90 μg, 60 μg, or 30 μg of the recombinant HPV 16/18 bivalent vaccine or the control hepatitis B vaccine on a 0, 1 and 6 month schedule. The designated doses are the combined micrograms of HPV16 and 18 VLPs with dose ratio of 2:1. The immunogenicity of the vaccines was assessed by measuring anti-HPV 16 and 18 neutralizing antibodies and total IgG antibodies. Safety of the vaccine was assessed.ResultsAll but one of the seronegative participants who received 3 doses of the HPV vaccines seroconverted at month 7 for anti-HPV 16/18 neutralizing antibodies and IgG antibodies. For HPV 16, the geometric mean titers (GMTs) of the neutralizing antibodies were similar between the 60 μg (GMT = 10,548) and 90 μg (GMT = 12,505) HPV vaccine groups and were significantly higher than those in the 30 μg (GMT = 7596) group. For HPV 18, the GMTs of the neutralizing antibodies were similar among the 3 groups. The HPV vaccine was well tolerated. No vaccine-associated serious adverse events were identified.ConclusionThe prokaryotic-expressed HPV vaccine is safe and immunogenic in women aged 18–25 years. The 60 μg dosage formulation was selected for further investigation for efficacy.Clinical trials registration: NCT01356823.